EP0651650A4 - PROCEDE POUR TRAITER DES AFFECTIONS OPHTALMIQUES A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE--g(b). - Google Patents

PROCEDE POUR TRAITER DES AFFECTIONS OPHTALMIQUES A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE--g(b).

Info

Publication number
EP0651650A4
EP0651650A4 EP93917021A EP93917021A EP0651650A4 EP 0651650 A4 EP0651650 A4 EP 0651650A4 EP 93917021 A EP93917021 A EP 93917021A EP 93917021 A EP93917021 A EP 93917021A EP 0651650 A4 EP0651650 A4 EP 0651650A4
Authority
EP
European Patent Office
Prior art keywords
tgf
ophthalmic disorders
treating ophthalmic
treating
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP93917021A
Other languages
German (de)
English (en)
Other versions
EP0651650A1 (fr
Inventor
Bert M Glaser
Bruce B Pharriss
Ann F Hanham
George A Ksander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of EP0651650A1 publication Critical patent/EP0651650A1/fr
Publication of EP0651650A4 publication Critical patent/EP0651650A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
EP93917021A 1992-07-08 1993-07-08 PROCEDE POUR TRAITER DES AFFECTIONS OPHTALMIQUES A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE--g(b). Ceased EP0651650A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91083492A 1992-07-08 1992-07-08
US910834 1992-07-08
US877893A 1993-01-22 1993-01-22
US8778 1993-01-22
PCT/US1993/006420 WO1994001124A1 (fr) 1992-07-08 1993-07-08 PROCEDE POUR TRAITER DES AFFECTIONS OPHTALMIQUES A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE-$g(b)

Publications (2)

Publication Number Publication Date
EP0651650A1 EP0651650A1 (fr) 1995-05-10
EP0651650A4 true EP0651650A4 (fr) 1996-04-17

Family

ID=26678611

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93917021A Ceased EP0651650A4 (fr) 1992-07-08 1993-07-08 PROCEDE POUR TRAITER DES AFFECTIONS OPHTALMIQUES A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE--g(b).

Country Status (5)

Country Link
EP (1) EP0651650A4 (fr)
JP (1) JPH08502033A (fr)
AU (1) AU4668193A (fr)
CA (1) CA2138644A1 (fr)
WO (1) WO1994001124A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
WO1995009003A1 (fr) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions contenant des facteurs de croissance et des antimetabolites
WO1995009004A1 (fr) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions contenant des facteurs de croissance et des agents antiplastiques
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
WO2001009327A2 (fr) * 1999-07-28 2001-02-08 Genentech, Inc. Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
WO1998024468A1 (fr) * 1996-12-04 1998-06-11 Clark Abbot F TGFα UTILISE POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME
AU8656098A (en) * 1997-07-23 1999-02-16 Brigham And Women's Hospital Lens epithelial cell derived growth factor
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
NZ511559A (en) * 1998-11-23 2004-01-30 Novartis Ag Use of staurosporine derivatives for treating ocular neovascular diseases
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
AU2001228863A1 (en) * 2000-01-31 2001-08-14 Santen Pharmaceutical Co. Ltd. Remedies for ophthalmic diseases
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
KR20150083117A (ko) 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
CN110302004B (zh) 2013-05-03 2023-04-28 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
RU2540504C1 (ru) * 2013-12-26 2015-02-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития поздней отслойки сетчатки у детей с рубцовой ретинопатией недоношенных
US20170080030A1 (en) * 2014-03-17 2017-03-23 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
EP3413851B1 (fr) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Emballage
CA3062845A1 (fr) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systemes et methodes pour l'administration de medicaments par voie ophtalmique
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
CN111803623A (zh) * 2020-07-31 2020-10-23 重庆康视美科技有限公司 一种治疗近视的生物制剂及其制备方法、使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002247A1 (fr) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Methode de traitement des blessures endotheliales corneennes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002247A1 (fr) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Methode de traitement des blessures endotheliales corneennes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONNOR T.B. ET AL.: "Correlation of Fibrosis and Transforming Growth Factor-beta Type 2 Levels in the Eye", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 85, no. 5, pages 1661 - 1666, XP002047092, DOI: doi:10.1172/JCI114065 *
JAMPEL H D ET AL: "TRANSFORMING GROWTH FACTOR -BETA IN HUMAN AQUEOUS HUMOR.", CURR EYE RES 9 (10). 1990. 963-970. *
See also references of WO9401124A1 *
TRIPATHI R C ET AL: "Role of Growth Factors in the Uveal Tract of the Eye as Targeted to the Development of Nw Drugs", DRUG DEV RES 23(1). 1991. 1-25. *

Also Published As

Publication number Publication date
EP0651650A1 (fr) 1995-05-10
AU4668193A (en) 1994-01-31
WO1994001124A1 (fr) 1994-01-20
CA2138644A1 (fr) 1994-01-20
JPH08502033A (ja) 1996-03-05

Similar Documents

Publication Publication Date Title
EP0651650A4 (fr) PROCEDE POUR TRAITER DES AFFECTIONS OPHTALMIQUES A L'AIDE DU FACTEUR TRANSFORMANT DE CROISSANCE--g(b).
US5281607B1 (en) Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB2265399B (en) Horizontal well treatment method
EP0820467A4 (fr) Procedes de traitement de troubles oculaires
AU1935395A (en) Method for treating conditions of the eye using polypeptides
GB2233996B (en) Well treatment method
EP0729361A4 (fr) Procede de traitement de troubles neurologiques
EP0630383A4 (fr) Procedes de traitement des diabetes.
EP0493037A3 (en) Method of treating thromboembolic disorders
EP0610444A4 (fr) Procede de traitement de maladies virales.
ZA931063B (en) Treatment of glaucoma.
ZA965346B (en) Methods of treating neuropeptide Y-associated conditions.
EP0732938A4 (fr) Procede pour traiter des troubles intestinaux
ZA9010081B (en) Method for the treatment of glaucoma
EP0608702A3 (fr) Procédé de traitement des noisettes.
GB2265833B (en) Myopia therapy apparatus
GB9201391D0 (en) Method of treatment
AU2269392A (en) Method for treating immunological disorders and diseases
AU2321088A (en) Method for preventing or treating thrombocytopenia
GB9218597D0 (en) Novel method of treatment
RU1785687C (ru) Cпocoб лeчehия глoccaлгии
GB9223953D0 (en) Treatment of eye disorders
GB9226252D0 (en) Method of treatment
GB9223252D0 (en) Method of treatment
GB9218188D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: A61K 38/00

RHK1 Main classification (correction)

Ipc: A61K 37/02

A4 Supplementary search report drawn up and despatched

Effective date: 19960304

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980730

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19991211